Cellular Generation and Phenotyping | Scientific Operations

Cellular Generation and Phenotyping | Scientific Operations

Cellular Generation and Phenotyping

Cellular Generation and Phenotyping group 2019, Wellcome Sanger Institute
Cellular Generation and Phenotyping group 2019, Wellcome Sanger Institute

Our Research and Approach

The Cellular Generation and Phenotyping (CGaP) core facility provides central cell biology support to the Sanger Institute. CGaP takes a unique approach at the institute by partnering with faculty groups in order to deliver the scale-up of existing protocols to facilitate 'Science at Scale'. We function as a contract research group for the institute, running multiple, distinct cell biology based projects. The facility has expertise in cell derivation from primary tissue, iPSC and organoid derivation, cellular differentiation, CRISPR library screening, functional bioassays, phenotypic assays and end point analysis (e.g. Immunocytochemistry).

Read More

People

Dr Rachel Nelson
Group Leader

Head of CGaP, Cellular Generation & Phenotyping Core Facility

Govan, Ceri

Govan, Ceri
Ceri Govan
Principal Technical Assistant
Show Alumni

Alumni

Key Projects, Collaborations, Tools & Data

The team are currently involved with a number of major projects at the Sanger Institute including Human Cancer Model Initiative (HCMI), Deciphering Developmental Disorders (DDD) and Human Cell Atlas.

Programmes, Associate Research Programmes and Facilities

Partners and Funders

Internal Partners
External Partners and Funders

Publications

  • Successful Generation of Human Induced Pluripotent Stem Cell Lines from Blood Samples Held at Room Temperature for up to 48 hr.

    Agu CA, Soares FA, Alderton A, Patel M, Ansari R et al.

    Stem cell reports 2015;5;4;660-71

  • Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting.

    Iorio F, Behan FM, Gonçalves E, Bhosle SG, Chen E et al.

    BMC genomics 2018;19;1;604

  • Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics.

    Li X, Francies HE, Secrier M, Perner J, Miremadi A et al.

    Nature communications 2018;9;1;2983

  • Rapid establishment of the European Bank for induced Pluripotent Stem Cells (EBiSC) - the Hot Start experience.

    De Sousa PA, Steeg R, Wachter E, Bruce K, King J et al.

    Stem cell research 2017;20;105-114

  • Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

    Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM et al.

    Nature 2019;568;7753;511-516

  • A Compendium of Mutational Signatures of Environmental Agents.

    Kucab JE, Zou X, Morganella S, Joel M, Nanda AS et al.

    Cell 2019;177;4;821-836.e16

  • Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening.

    Picco G, Chen ED, Alonso LG, Behan FM, Gonçalves E et al.

    Nature communications 2019;10;1;2198